The recent publication by Kelly et al. (1998) of their study on sucrose polyesters (SPE) raised concerns about the possible gastrointestinal (GI) and nutritional effects of olestra. These concerns were echoed in the popular press ('Doubts raised over anti-obesity fat substitute'. The Times, 11 August 1998.). Olestra's potential to cause GI and nutritional effects has been carefully reviewed by the US Food and Drug Administration (FDA), including two public meetings of the FDA Foods Advisory Committee in November 1995 and again in June 1998. The recent comprehensive committee review included results from US marketplace surveillance and from new clinical research. The committee reaffirmed, by an overwhelming majority, their decision that olestra snacks are safe. In light of this favourable review and the acceptance of olestra snacks by US consumers, we would like to make several specific points regarding the publication by Kelly et al. (1998) .
First, it should be made very clear that Kelly and colleagues tested SPE produced by Unilever which are substantially different from olestra manufactured by Procter & Gamble and approved by the FDA for use in savoury snacks. A significant error in this regard was stated by Kelly et al. (1998) '…SPE was approved by the United States Food and Drug Administration for use in savoury snack foods'.
Although olestra falls into the broader class of SPE, the olestra which was approved by the FDA has very specific composition requirements which set it apart from other SPE. The FDA's compositional requirements for olestra include a specification to prevent anal oil-leakage. The liquid SPE used by Kelly and colleagues in the margarine, biscuits, cake, cheese, chocolate spread, peanut butter, and salad cream consumed in the study would not pass this specification, and would therefore cause anal oil-leakage. Therefore, the findings by Kelly et al. (1998) of 'anal leakage' in 7⋅2 % of subjects should not be assumed to be relevant to olestra. Further, studies conducted by Procter & Gamble to elucidate the relationship between GI symptoms experienced when eating SPE which is liquid at room temperature and those noted after eating olestra as specified in the US FDA regulation have shown that liquid SPE associated with 'anal leakage' are also associated with increased incidence of GI symptoms (data on file, Procter & Gamble). Second, the study by Kelly et al. (1998) involved daily ingestion of large amounts of SPE in a variety of foods that would be eaten at essentially every meal. This regimen differs markedly from use of olestra in savoury snacks which are consumed much less frequently and with only a fraction of meals. Several randomized placebo-controlled studies have specifically addressed whether ingestion of olestra snacks will increase GI symptoms in consumers. Cheskin et al. (1998) studied 1092 subjects eating as much as they wanted (up to 13 ounces (about 368 g)) on a single eating occasion of olestra potato chips or placebo, full-fat chips. There were no significant differences in the occurrence or severity of GI symptoms between the subjects who consumed olestra chips and those who consumed full-fat chips. In another double-blind study, 3181 children, teenagers, and adults were allowed to eat essentially unlimited amounts of olestra snacks for 6 weeks (Sandler, 1998) . There was no overall significant difference in the incidence of GI symptoms, with the exception of increased nausea in the full-fat group. The mean number of symptom days during the 6-week period was not different between groups except for the number of days on which 'more frequent bowel movements' were reported (3⋅7 v. 2⋅8 d, olestra v. full-fat). There was no difference in the impact of GI symptoms on the daily activity assessment ratings between the two groups. It is worth noting that there were no reports of 'anal leakage' in either of these two studies.
Third, Kelly et al. (1998) raised the question of whether there are safety concerns in persons with underlying GI disorders. Zorich et al. (1997) conducted a specific study in persons with inflammatory bowel disease that assessed whether olestra may have adverse health effects on potentially sensitive subpopulations with bowel disease. Eighty-nine patients with mild to moderate ulcerative colitis (n 43) or Crohn's disease (n 46) were randomly assigned to eat 20 g olestra in chips and cookies for 4 consecutive weeks, or equivalent full-fat products. There was no difference with respect to disease activity, and GI symptoms were comparable between the treatment groups. Marketplace surveillance has not revealed any patterns indicating groups of people who are intolerant to olestra. Controlled rechallenge testing of people reporting digestive effects in the marketplace has shown no differences in digestive effects when these people were eating olestra v. full-fat chips and that they were not uniquely intolerant to olestra (Zorich et al. 1998) .
Based on the results reported by Kelly et al. (1998) , it is unclear how they came to the conclusion that there were 'important deleterious' GI effects from the SPE. For example, the authors state that no subjects discontinued the study because of adverse effects. The authors state that bowel movement frequency increased from seven bowel movements per week to ten. This is still well within what would be considered a normal range for a healthy adult in the UK. Importantly, the authors monitored 'general well-being scores' during the study which were not lower when the participants consumed SPE. In addition, a variety of routine and more sophisticated studies were conducted, i.e. rectal tissue biopsies, small-bowel biopsies, liver function studies, and a large variety of screening blood chemistry and haematologic tests. No health concerns were identified by any of these tests.
The reduction in serum carotenoid levels measured in this study when a large variety of SPE-containing foods were co-consumed with carotenoid-containing foods is consistent with what has been measured in previous studies by Proctor & Gamble with olestra (Koonvitsky et al. 1997; Schlagheck et al. 1997) and by Unilever with SPE (Westrate & van het Hof, 1995) . However, an analysis of nearly 4000 snack consumers has indicated that the frequency of coconsumption of olestra snacks and carotenoid foods is such that consumption of olestra in savoury snacks will not alter carotenoid levels meaningfully (Cooper et al. 1997) .
The results of this study further reinforce that fatreplacers have a potential positive role to play in the diet. The study by Kelly et al. (1998) showed a reduction in dietary fat consumption, a reduction in serum cholesterol, and a highly significant (P Ͻ 0⋅001) lower body weight after 12 weeks of SPE consumption. This is consistent with recent work by Hill et al. (1998) and Miller et al. (1998) which showed a reduction in fat and energy consumption when olestra replaced some of the fat in the diet. Surprisingly, Kelly et al. (1998) 
Sucrose polyester in human volunteers -reply by Kelly & Hunter
We have read the letter by Zorich and colleagues with interest. It is true that sucrose polyesters (SPE) may vary slightly in their chemical composition, but the analytical data on the SPE used in our study showed that their chemical characteristics were similar to the olestra approved by the US Food and Drug Administration (FDA). They were slightly less viscous than the olestra SPE, and therefore liable to cause anal leakage. Our study differed from those reported by Proctor & Gamble in that there was a fairly large average daily SPE intake in many different products as opposed to a single savoury snack. However, we believe this to be more representative of what might happen if SPE products were freely available.
Proctor & Gamble themselves have emphasized the frequency of digestive symptoms in the general population (Sandler et al. 1998a) . To detect the effects of SPE on the gut against this background it is necessary to perform crossover studies, ideally in subjects with no previous bowel symptoms. Using this technique we found clear evidence of an increase in stool frequency, urgency and flatulence and after 8 weeks a significant incidence of abdominal pain. The studies quoted by Zorich et al. (Cheskin et al. 1998 , Sandler et al. 1998b ), which were not cross-over studies, were inevitably less sensitive than ours. Patients with inflammatory bowel disease (Zorich et al. 1997) are not representative as their bowel function is controlled by powerful medication. Although the dose and type of SPE ingested may influence symptoms, we see no reason to change our conclusion that there can be important gastrointestinal effects from SPE.
All reports so far published confirm that SPE ingestion leads to reduced plasma concentrations of carotenoids. Westrate & van het Hof (1995) found that as little as 3 g SPE/d was sufficient to have this effect. There is anxiety that patients with reduced carotenoid concentrations may be more likely to develop neoplasms (Wald et al. 1988; Connett et al. 1989) .
We believe that the proposed health benefits of SPE still need further confirmation. The weight loss in our subjects was statistically significant, but clinically unimportant. We know of no evidence that reduction in the serum cholesterol in subjects with a normal concentration provides any further benefit and those with hypercholesterolaemia or ischaemic heart disease will still require pharmacological treatment. The letter by Zorich, Allgood and Peters has not changed our view that our findings merit careful consideration is assessing the long-term health effects of SPE-containing foods.
